SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
Open Access
- 17 February 2021
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 5 (3), e547
- https://doi.org/10.1097/hs9.0000000000000547
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- COVID-19 vaccine race: watch your step for cancer patientsBritish Journal of Cancer, 2021
- Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2Annals of Oncology, 2021
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkLeukemia, 2021
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setBlood, 2020
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemiaLeukemia, 2020
- Low prevalence of IgG antibodies to SARS‐CoV‐2 in cancer patients with COVID‐19International Journal of Cancer, 2020
- Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19Annals of Oncology, 2020